share_log

CORRESP: CORRESP

CORRESP: CORRESP

CORRESP:信函
美股SEC公告 ·  2024/09/10 10:33

Moomoo AI 已提取核心訊息

ZyVersa Therapeutics, Inc. has officially requested the U.S. Securities and Exchange Commission (SEC) to declare its Registration Statement on Form S-3 effective as of September 9, 2024, at 5:00 p.m. Eastern Time. The request, made under Rule 461 of the Securities Act of 1933, was submitted through a correspondence filed via EDGAR. ZyVersa Therapeutics, located at 2200 N. Commerce Parkway, Suite 208, Weston, Florida, has indicated that the effective date and time are subject to change if the company provides prior notification to the SEC. The company's Chief Executive Officer, Stephen C. Glover, signed the request, and any inquiries regarding this matter are to be directed to Faith L. Charles of Thompson Hine LLP, the company's outside counsel.
ZyVersa Therapeutics, Inc. has officially requested the U.S. Securities and Exchange Commission (SEC) to declare its Registration Statement on Form S-3 effective as of September 9, 2024, at 5:00 p.m. Eastern Time. The request, made under Rule 461 of the Securities Act of 1933, was submitted through a correspondence filed via EDGAR. ZyVersa Therapeutics, located at 2200 N. Commerce Parkway, Suite 208, Weston, Florida, has indicated that the effective date and time are subject to change if the company provides prior notification to the SEC. The company's Chief Executive Officer, Stephen C. Glover, signed the request, and any inquiries regarding this matter are to be directed to Faith L. Charles of Thompson Hine LLP, the company's outside counsel.
ZyVersa Therapeutics, Inc.已正式要求美國證券交易委員會(SEC)於2024年9月9日下午5:00(東部時間)起使其S-3表格註冊聲明生效。該請求根據1933年證券法第461條規定通過EDGAR提交的函電。總部位於佛羅里達州韋斯頓市N. Commerce Parkway 2200號208套間的ZyVersa Therapeutics已指出,如果公司事先向SEC提供通知,則生效日期和時間可能會有所更改。該公司的首席執行官Stephen C. Glover簽署了該請求,關於此事的任何查詢都應轉至該公司外部律師事務所Thompson Hine LLP的Faith L. Charles。
ZyVersa Therapeutics, Inc.已正式要求美國證券交易委員會(SEC)於2024年9月9日下午5:00(東部時間)起使其S-3表格註冊聲明生效。該請求根據1933年證券法第461條規定通過EDGAR提交的函電。總部位於佛羅里達州韋斯頓市N. Commerce Parkway 2200號208套間的ZyVersa Therapeutics已指出,如果公司事先向SEC提供通知,則生效日期和時間可能會有所更改。該公司的首席執行官Stephen C. Glover簽署了該請求,關於此事的任何查詢都應轉至該公司外部律師事務所Thompson Hine LLP的Faith L. Charles。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息